Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Arkansas Research Trials

Neither a doctor nor a teaching hospital

Research payments

$330,565

166 payments

Through program year 2025, Arkansas Research Trials is reported as receiving $330,565 in research payments, across 166 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $163,125 30
2024 Research $74,705 98
2023 Research $68,483 34
2022 Research $24,170 3
2021 Research $81 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $178,647 7 payments
  2. Incyte Corporation $41,323 38 payments
  3. Daiichi Sankyo Company LTD $40,616 7 payments
  4. E.R. Squibb & Sons, L.L.C. $34,194 5 payments
  5. Daiichi Sankyo Inc. $22,580 105 payments
  6. Sanofi US Services Inc. $10,824 1 payment
  7. GlaxoSmithKline, LLC. $1,500 1 payment
  8. Amgen Inc. $724 1 payment
  9. AbbVie, Inc. $157 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S $131,960 1 payment
  2. Ds7011-107 $34,911 107 payments
  3. A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages 12 Years to 18 Years) With Atopic Dermatitis $32,836 7 payments
  4. Ds-7011-107 $28,285 5 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $23,802 1 payment
  6. A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE $19,053 2 payments
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting $15,141 3 payments
  8. A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $11,794 2 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $11,090 3 payments
  10. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $10,824 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record